Unicycive Therapeutics, Inc. (UNCY) — SEC Filings
Unicycive Therapeutics, Inc. (UNCY) — 50 SEC filings. Latest: ARS (Apr 30, 2026). Includes 23 8-K, 7 SC 13G/A, 6 10-Q.
View Unicycive Therapeutics, Inc. on SEC EDGAR
Overview
Unicycive Therapeutics, Inc. (UNCY) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a ARS filed on Apr 30, 2026: Unicycive Therapeutics, Inc. filed its Annual Report to Security Holders (ARS) on April 30, 2026, for the period ending December 31, 2025. The company is based in Mountain View, California, and operates in the Pharmaceutical Preparations sector.
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 45 neutral, 2 mixed. The dominant filing sentiment for Unicycive Therapeutics, Inc. is neutral.
Filing Type Overview
Unicycive Therapeutics, Inc. (UNCY) has filed 1 ARS, 4 DEFA14A, 23 8-K, 3 10-K, 6 10-Q, 2 DEF 14A, 1 8-K/A, 7 SC 13G/A, 3 SC 13G with the SEC between Feb 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of UNCY's 39 recent filings, 4 were flagged as high-risk, 10 as medium-risk, and 25 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | Not Disclosed |
| EPS | Not Disclosed |
| Debt-to-Equity | Not Disclosed |
| Cash Position | Not Disclosed |
| Operating Margin | Not Disclosed |
| Total Assets | Not Disclosed |
| Total Debt | Not Disclosed |
Key Executives
- Chief Executive Officer
Industry Context
Unicycive Therapeutics operates in the highly competitive biotechnology sector, focusing on the niche but significant area of kidney disease therapies. The company's strategy of in-licensing assets is common in the industry, aiming to leverage existing technologies and reduce early-stage R&D risk. Key trends include the increasing prevalence of chronic diseases like CKD and the persistent unmet need in areas like AKI, driving demand for innovative treatments.
Top Tags
8-K (9) · regulatory-filing (8) · pharmaceuticals (4) · sec-filing (4) · corporate-governance (4) · proxy-statement (4) · 10-Q (4) · 8-k (3) · Biotechnology (3) · filing-update (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Period of Report | 2025-12-31 | Indicates the end date for the financial reporting period. |
| Filing Date | 2026-04-30 | The date the report was officially submitted to the SEC. |
| Market Value | $64.3M | Aggregate market value of non-affiliate voting stock as of June 30, 2025, indicating current market capitalization. |
| Shares Outstanding | 25.2M | Number of common stock shares outstanding as of March 30, 2026, relevant for per-share calculations. |
| PDUFA Target Date | June 29, 2026 | Critical FDA target action date for oxylanthanum carbonate NDA, directly impacting potential market entry. |
| Product Revenue | 0 | Product revenue generated to date, highlighting the company's pre-commercial stage and reliance on pipeline success. |
| Americans with CKD | 36M | Number of Americans affected by Chronic Kidney Disease, representing the target market size for OLC. |
| ESRD Patients | 550K | Number of Americans with end-stage renal disease requiring dialysis, a subset of the target market for OLC. |
| Dialysis Patients on Phosphate Binders | 450K | Estimated number of U.S. dialysis patients taking phosphate binders, indicating the immediate addressable market for OLC. |
| AKI Patients | 2M | Number of U.S. patients affected by Acute Kidney Injury annually, representing the target market for UNI-494. |
| AKI Healthcare Cost | $9B | Annual cost to the U.S. healthcare system due to AKI, highlighting the economic burden UNI-494 aims to address. |
| Uncontrolled Hyperphosphatemia | 75% | Percentage of U.S. dialysis patients with uncontrolled hyperphosphatemia, underscoring the unmet medical need OLC targets. |
| Net Loss | $6.011M | for the three months ended September 30, 2025, increased from $4.096M in 2024 |
| Cash and Cash Equivalents | $42.695M | as of September 30, 2025, up from $26.142M at December 31, 2024 |
| Net Proceeds | $38.6M | from secondary public offering during the nine months ended September 30, 2025 |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Unicycive Therapeutics, Inc. (UNCY)?
Unicycive Therapeutics, Inc. has 50 recent SEC filings from Feb 2024 to Apr 2026, including 23 8-K, 7 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of UNCY filings?
Across 50 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 45 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Unicycive Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Unicycive Therapeutics, Inc. (UNCY) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Unicycive Therapeutics, Inc.?
Key financial highlights from Unicycive Therapeutics, Inc.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for UNCY?
The investment thesis for UNCY includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Unicycive Therapeutics, Inc.?
Key executives identified across Unicycive Therapeutics, Inc.'s filings include Chief Executive Officer.
What are the main risk factors for Unicycive Therapeutics, Inc. stock?
Of UNCY's 39 assessed filings, 4 were flagged high-risk, 10 medium-risk, and 25 low-risk.
What are recent predictions and forward guidance from Unicycive Therapeutics, Inc.?
Forward guidance and predictions for Unicycive Therapeutics, Inc. are extracted from SEC filings as they are enriched.